Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a report published on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The company has a market cap of $833,000.00, a P/E ratio of -0.01 and a beta of -0.90. Athersys has a 1 year low of $0.01 and a 1 year high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.